very promising17 Mar 2013 22:14
Director buying in the last 5 years
The total shares and average share price for all director dealings is (till date) suggests that BoD will support the rise of this stock price.
Name.................Shares.....Ave Per share...Deal size in 1000 (GBP)
C E Cattaneo.........900,000....3.915555556.....£35.24
C H Rollins..........101,923....6.092834787.....£6.21
C T Croskery.........831,498....4.44980024......£37
M Emberton...........319,932....3.975844867.....£12.72
O M A Karim..........3,901,110..6.906752181.....£269.44
Mark Hughes..........150,000....3.25............£4.88
P G Stimpson.........6,073,441..4.05332.........£246
Note - P G Stimpson has total stake of 24,318,021 (17.26%)
What's so unique about Mediwatch
1. Mediwatch, as a “One-stop Shop”, designs, manufactures, and sells a wide array of urology diagnostic products.
2. World wide sales network - Mediwatch utilizes direct sales forces in both the USA and UK, and manages a distribution network of 80 dealers worldwide - North
America, Europe, the Far East, Central and South America, the Middle East, Africa and Australia.
3. Refer to NHS Evaluation report below
The evaluation report covers 26 urodynamic systems commercially available within UK. The national guidance was from National Institute for Health and Clinical Excellence (NICE). In this report Mediwatch received a - FIVE STAR for Usability/Operational considerations for two criteria and FOUR STAR for remaining four criteria. Only supplier to get FIVE STAR in this section.
The evaluation report link - http://www.biomedhtc.org.uk/BuyerGuides/CEP09038-Urodynamic-Systems-Evaluation-Report.pdf
4. Deals with CR Bard, Acon and Thought Technology. And the recent JV with Genesis
5. Supplying equipment and services for drugs trials with the pharmaceutical majors on a multi-year contract basis.